ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1457	National Cancer Institute	Html	en	Esophageal Cancer Prevention (PDQ®)–Patient Version	Expert-reviewed information summary about factors that may influence the risk of developing esophageal cancer and about research aimed at the prevention of this disease.	cancer treatment 0.286725 cancer prevention trials 0.390926 protective factors 0.401778 following PDQ summaries 0.346585 PDQ cancer information 0.534006 Clinical Trials section 0.298655 esophageal cancer prevention 0.457641 clinical trials 0.60082 kidney damage 0.286456 cancer information summary 0.441092 lower esophagus 0.410035 lower sphincter muscle 0.357661 breast cancer prevention 0.318294 patients 0.3021 cancer patients 0.287439 latest published information 0.293022 cancer risk factor 0.360882 NCI’s PDQ 0.303811 NCI PDQ cancer 0.377375 stomach acid 0.297556 radiofrequency ablation 0.407628 PDQ Screening 0.291859 abnormal cells 0.372908 cancer risk factors 0.361881	Cancer prevention 0.541167 esophageal cancer 0.615396 cancer protective factor 0.339428 esophageal cancer increases 0.350762 Barrett esophagus 0.51844 Cancer Information Service 0.327169 prevention clinical trials 0.346293 Prevention Editorial Board 0.348856 treatment clinical trials 0.298225 National Cancer Institute 0.429589 Nonsteroidal anti-inflammatory drugs 0.365737 PDQ documents 0.293539 new treatment 0.29433 Cancer Care page 0.315656 PDQ database 0.297589 adenocarcinoma 0.336667 PDQ summary 0.318797 cancer clinical trials 0.340291 risk factors 0.504317 cancer information summaries 0.334653 comprehensive cancer information 0.334858 cancer 0.918802 esophagus produce 0.402126 esophagus 0.723728	CLICK HERE
1477	National Cancer Institute	Html	en	Bladder Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of bladder cancer.	Ta T1 bladder 0.556554 T1 high-grade bladder 0.506904 superficial bladder tumour 0.53364 bacillus calmette-guerin 0.516715 transitional cell carcinoma 0.695076 T1 transitional cell 0.496806 bladder cancer 0.986423 der Meijden AP 0.500317 clinical trials 0.520234 intravesical bacillus Calmette-Guerin 0.513656 primary superficial bladder 0.615094 non-muscle invasive bladder 0.495804 T1 bladder cancer 0.609466 Malignant bladder tumors 0.513021 superficial bladder cancer 0.787159 bladder tumors 0.61916 van der Meijden 0.529014 patients 0.562152 advanced bladder cancer 0.510311 Invasive T1 bladder 0.497584 high-grade T1 bladder 0.499638 newly diagnosed bladder 0.507837 superficial bladder tumors 0.5725 bacillus calmette-guerin therapy 0.514624	metastatic bladder cancer 0.563646 Canadian Bladder Cancer 0.508472 et al. 0.600299 bladder carcinogenesis 0.499935 high-grade bladder cancer 0.517381 bladder cancer. 0.49995 Eur Urol 0.553395 PUBMED Abstract 0.561063 invasive bladder cancer 0.614868 radical cystectomy 0.523916 non-muscle-invasive bladder cancer 0.573969 transurethral resection 0.509808 bladder cancer coincides 0.50967 advanced bladder carcinoma 0.508345 Abstract 0.681067 Herr HW 0.527009 Clin Oncol 0.566437 bladder carcinoma 0.546923 Urol 0.572506 urothelial carcinoma 0.574639 invasive bladder carcinoma 0.507022 nonmuscle-invasive bladder cancer 0.533359 Low-grade bladder cancers 0.509091 bladder cancer health 0.52478	CLICK HERE
1604	National Cancer Institute	Html	en	Bladder and Other Urothelial Cancers Screening (PDQ®)–Patient Version	Expert-reviewed information summary about tests used to detect or screen for bladder cancer.	red blood cells 0.494369 cancer treatment 0.489394 bladder cancers 0.541229 urine 0.494083 ongoing clinical trials 0.492966 bladder urothelium 0.575205 following PDQ summaries 0.556519 Transitional cell carcinoma 0.483769 PDQ cancer information 0.750577 cancer increases 0.491939 false-negative test result 0.489029 bladder cancer 0.812624 clinical trials 0.684635 test result 0.523443 special test strip 0.489962 cancer information summary 0.626401 clinical trial 0.502183 breast cancer prevention 0.514992 false-positive test result 0.488801 cancer patients 0.484495 latest published information 0.497666 NCI’s PDQ 0.51339 cancer symptoms 0.50531 NCI PDQ cancer 0.589485	tests 0.518118 Squamous cell carcinoma 0.486084 PDQ Screening 0.538371 screening tests 0.491835 Cancer Information Service 0.53331 urothelial cancers 0.536876 PDQ Bladder 0.571685 Prevention Editorial Board 0.549647 treatment clinical trials 0.491831 National Cancer Institute 0.634201 PDQ documents 0.50321 cell carcinoma 0.486793 new treatment 0.498073 Cancer screening trials 0.570719 Cancer Care page 0.519283 PDQ database 0.508182 risk factor 0.512484 PDQ summary 0.54439 cells 0.496479 cancer information summaries 0.541898 comprehensive cancer information 0.541535 renal pelvis 0.488981 cancer 0.961972 Urothelial Cancers Screening 0.519534	CLICK HERE
1705	National Cancer Institute	Html	en	Cancer Vaccines	A fact sheet discussing how cancer vaccines are used to harness the body’s immune system to protect against cancer-causing viruses and as immunotherapy to treat existing cancers.	vaccines target 0.540823 Anti-cancer vaccines 0.524975 abnormal cells 0.538771 antitumor immune response 0.513051 cancer vaccines 0.904526 specific immune responses 0.519605 traditional vaccines 0.550486 cancer cells 0.789704 allogeneic vaccines 0.526888 human papillomavirus vaccines 0.559079 multiple vaccines 0.540847 immune responses 0.691208 killer T cells 0.622141 M. Cancer vaccines 0.584037 cancer-associated antigens 0.612713 dendritic cells 0.519133 white blood cells 0.606559 immune response 0.721657 cancer treatment vaccine 0.564337 dendritic cell vaccines 0.544937 immune checkpoint 0.531831 clinical trials 0.608279 anticancer vaccines 0.541706 anticancer immune response 0.511669	tumor cells 0.510012 anticancer immune responses 0.598324 effective treatment vaccines 0.575167 normal cells 0.555313 metastatic prostate cancer 0.537182 cancer treatment vaccines 0.999587 anti-idiotype vaccines 0.527061 prostate cancer cells 0.562932 immune cells 0.566337 cancer preventive vaccines 0.728942 cancer antigens 0.523547 tumor cell vaccines 0.548556 Forni G. Vaccines 0.537061 cells 0.810385 cytotoxic t cells 0.520347 Clinical Cancer Research 0.524363 strong immune response 0.509393 et al 0.519859 immune system cells 0.584226 cancer preventive vaccine 0.510434 current vaccines 0.524179 therapeutic cancer vaccines 0.612595 natural immune response 0.518594	CLICK HERE
1713	National Cancer Institute	Html	en	Mammograms	A fact sheet that defines screening and diagnostic mammograms; discusses the benefits and potential harms of screening mammograms; and summarizes how findings, including breast density, are reported.	mammography facility 0.617711 randomized breast screening 0.57821 mammograms 0.675286 tomosynthesis mammography 0.551922 3-D mammography 0.578436 health care provider 0.558006 breast implants 0.579825 clinical breast exams 0.637306 low-cost screening mammogram 0.569796 FDA-certified mammography facilities 0.561341 breast cancers 0.551598 dense breasts 0.550925 mammography screening programs 0.6099 diagnostic mammography 0.569303 conventional mammography 0.61609 standard digital mammography 0.569915 diagnostic mammogram 0.562845 high breast density 0.542253 mammography screening 0.620292 breast tissue 0.554504 Breast Imaging Reporting 0.535488 local mammography facility 0.561875 Regular breast self-exam 0.536763 mammogram 0.686942	breast cancer screening. 0.555392 digital mammography 0.659536 breast size 0.53014 regular screening mammography 0.636566 Mammography Quality Standards 0.561193 diagnostic mammograms 0.537673 digital breast tomosynthesis 0.539944 breast pain 0.528266 False-positive mammogram results 0.54885 mammography facilities 0.595109 breast cancer screening 0.594468 mammography 0.783904 breast density 0.567834 breast cancer 0.951318 annual screening mammograms 0.562698 standard mammography 0.551771 2-D mammography 0.551301 high-quality screening mammograms 0.56602 Mammography Imaging Screening 0.608506 previous breast biopsies 0.545681 screening mammogram 0.619625 false-negative results 0.544234 mammography providers 0.542876	CLICK HERE
1723	National Cancer Institute	Html	en	Cell Phones and Cancer Risk	A fact sheet that outlines the available evidence regarding use of cellular/mobile telephones and cancer risk.	study participants 0.44259 Self-reported cell phone 0.407518 past cell phone 0.400866 cell phone calls 0.471967 interphone study 0.417191 cell phone subscribers 0.456865 brain glucose metabolism 0.405692 brain tumors 0.529155 case-control study 0.507596 typical cell phone 0.408953 radiofrequency electromagnetic radiation 0.493663 radiofrequency energy exposure 0.501417 cell phone service 0.411175 radiofrequency energy 0.823507 brain cancer 0.549627 cell phone exposure 0.408273 mobile phone radiation 0.402738 cell phone base 0.419397 mobile phone 0.45428 specific absorption rate 0.399693 GSM mobile phone 0.393442 glucose metabolism 0.4091 Brain cancer incidence 0.408493 brain tumor incidence 0.393633 cell phone user 0.438311	study 0.591826 cohort study 0.434065 United States 0.44975 epidemiologic studies 0.488267 brain tumor risk 0.390841 cell phone 0.960278 cell phone technology 0.436997 National Cancer Institute 0.439672 long-term cell phone 0.404741 cell phones 0.77677 international case-control study 0.404344 prospective cohort study 0.39373 brain tumor 0.434845 brain cancer risk 0.419878 brain 0.559028 regular cell phone 0.406823 non-ionizing radiation 0.395758 cell phone radiofrequency 0.472899 cell phone users 0.536299 cell phone records 0.414439 et al 0.586681 cancer risk 0.424868 cancer 0.54982 risk 0.454009	CLICK HERE
1807	National Cancer Institute	Html	es	Tratamiento de la leucemia linfoblástica aguda infantil (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de la leucemia linfoblástica aguda infantil.	Natl Acad Sci 0.307376 Pediatric Oncology 0.305639 cuadro clínico 0.310887 accessed august 0.319526 Cancer Statistics Review 0.318661 Sin embargo 0.315253 American Cancer Society 0.312133 células t 0.309906 acute lymphoblastic leukaemia 0.410489 childhood acute lymphoblastic 0.499677 Nat Rev Cancer 0.306219 Declining childhood 0.306804 Estados Unidos 0.313559 Natl Cancer Inst 0.305713 Howlader N 0.306702 cord blood from 0.305809 Nat Genet 0.357137 Childhood Oncology Group 0.313596 Smith MA 0.306166 SEER Cancer Statistics 0.320166 Lancet Oncol 0.309044 compromiso testicular manifiesto 0.308702 gen mll 0.318674 influences childhood 0.306473 leucemia aguda 0.314027	reordenamientos mll 0.307367 Lymphoblastic Leukemia Based 0.308731 Proc Natl Acad 0.307623 leucemia linfoblástica aguda 0.338126 Noone AM 0.306815 Pediatr Blood Cancer 0.327193 acute lymphocytic leukemia 0.309611 childhood leukaemia 0.319593 Chessells JM 0.307957 National Cancer Institute 0.329181 Genes Chromosomes Cancer 0.305628 with down 0.333227 childhood leukemia 0.309509 Hosking FJ 0.306858 Acute leukaemia 0.30596 sistema nervioso central 0.310053 Dutch Childhood Oncology 0.31389 childhood b-cell 0.31228 Krapcho M 0.307706 acute lymphoblastic leukemia 0.986055 leucemia mieloide aguda 0.30545 Mullighan CG 0.306442 minimal residual disease 0.306428 células b 0.314985	CLICK HERE
1903	National Cancer Institute	Html	es	Tratamiento del linfoma no Hodgkin infantil (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del linfoma no Hodgkin infantil.	siguientes procedimientos 0.533869 posibles efectos tardíos 0.429839 células madre 0.925937 posibles factores 0.42224 adultos jóvenes 0.471015 estadio iv 0.456127 Burkitt recién 0.429453 sistema linfático.Para 0.433317 faja ajustadora 0.424807 gen alk 0.453637 leucemia linfoblástica aguda 0.499911 estadio ii 0.457571 siguientes especialistas 0.421884 siguientes tipos 0.435023 rayos x 0.42189 después.ampliar ecografía 0.422758 enlace drugs approved 0.552427 niño ayuda 0.422955 Sudores nocturnos 0.425131 ondas sonoras 0.421599 células t 0.997508 efectos tardíos 0.61792 PDQ Efectos tardíos 0.432774 líquido cefalorraquídeo 0.752047	sección linfoma 0.486518 Linfoma folicular tipo 0.701733 linfocitos b 0.461134 La terapia 0.636115 encontrarlo.ampliar exploración 0.423664 determinados cambios 0.538253 PDQ Tratamiento 0.508964 líquido incoloro 0.436562 explorador tep 0.424899 siguientes factores 0.424861 sistema nervioso central 0.543338 proteína llamada cinasa 0.449366 mayores probabilidades 0.423685 Non-Hodgkin Lymphoma 0.486305 estadio i 0.458742 tipo paniculitis 0.446711 Estados Unidos 0.425103 estadio iii 0.456847 tejido linfoide 0.449965 ósea fabrica glóbulos 0.477114 almacena glóbulos 0.436048 células b 0.553761 Hodgkin infantil recidivante 0.525837	CLICK HERE
1922	National Cancer Institute	Html	es	Tratamiento del cáncer de próstata (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer de próstata.	paciente presente síntomas 0.437409 siguientes procedimientos 0.452293 dé tratamiento 0.439746 estadio iv 0.493208 hiperplasia prostática benigna 0.97293 ecografía transrectal 0.704162 pequeña cantidad 0.628387 peores efectos 0.412864 estadio ii 0.558135 siguientes tipos 0.419876 tumor dosis 0.421814 rayos x 0.418531 sistema urinario masculino 0.436824 ondas sonoras 0.422219 principal fuente 0.412408 características sexuales masculinas 0.423477 enlace medicamentos 0.465713 National Cancer Institute 0.412027 sustancia radiactiva llamada 0.426571 biopsia.ampliar ecografía 0.431707 Instituto Nacional 0.421293 estadios iia 0.418459	hormonas masculinas 0.458793 PDQ Tratamiento 0.424516 hormonas sexuales masculinas 0.442195 estadio iia 0.431816 siguientes problemas 0.426176 presente sección 0.409743 tejidos cercanos.A veces 0.421604 Physician Data Query 0.443132 posibles problemas 0.411863 Estados Unidos 0.4216 estadio iii 0.498677 linfadenectomía pélvica 0.487486 prostatectomía radical.ampliar resección 0.439705 aparato reproductor masculino 0.440962 siguientes sustancias 0.416831 hipertrofia prostática benigna 0.438255 alta intensidad 0.548873 prostatectomía retropúbica 0.464416 Ganas repentinas 0.423669 próstata solas 0.515159 siguientes pruebas 0.46951 siguientes estadios 0.460134	CLICK HERE
16652	National Cancer Institute	Html	en	Track 2: Oncology Product Research and Review for B.C. Oncologists	NCI and FDA collaborate to train physicians in aspects of drug, biologic, or device development and standards for assessing medical product safety. Learn more about this cancer training program.	regulatory research 0.59502 pre-screened pool 0.579358 related issues 0.586202 reviewer training 0.576269 FDA scientific review 0.753981 later potential exposure 0.734497 regulatory meetings 0.582894 permanent residency 0.578922 Medical Center Dr 0.681374 fellows 0.986099 application guidelines 0.556272 clinical trials 0.592135 translational research 0.577443 various courses 0.556327 grand rounds 0.56318 various regulatory activities 0.729982 Regulatory Review Fellowships 0.720449 Cancer Training 0.567352 branch chief 0.561743 clinical divisions 0.572535 FDA Centers 0.764003 Review list 0.568699 training program 0.574879 application materials 0.560557 relevant federal statutes 0.739941	formal training 0.600328 U.S. citizenship 0.583794 earliest start date 0.680448 particular product 0.577316 office meetings 0.559685 senior member 0.553306 regulatory presentations 0.582975 guidance document development 0.691126 designee 0.446918 basic bench science 0.743323 principal investigators 0.569533 medical product safety 0.755593 Office Phone 0.552001 NCI-FDA Research 0.556736 one-year program 0.583619 supplemental training 0.588935 division director 0.57667 efficacy 0.476236 limited human exposure 0.741021 FDA medical review 0.830025 device development 0.579671 broader patient population 0.734715 clinical reviews 0.569332 pharmacology/toxicology 0.443629	CLICK HERE